Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC AG Further Strengthens Supervisory Board

Published: Monday, December 31, 2012
Last Updated: Monday, December 31, 2012
Bookmark and Share
Appointment of Dr Irina Antonijevic and Mr Klaus Kühn.

4SC AG has announced the appointment of Dr Irina Antonijevic and Mr Klaus Kühn to the company's Supervisory Board.

In a by-election at Annual General Meeting of 4SC AG, Dr Antonijevic and Mr Kühn were elected to the Supervisory Board for the remaining term of Dr Jörg Neermann and Mr Günter Frankenne, who have stepped down from the Supervisory Board.

The terms of office will run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for financial year 2012.

Dr Antonijevic, Director Clinical Research at US pharmaceutical company Sanofi, has many years of international experience in clinical drug development and extensive expertise gained in executive positions both in the pharmaceutical industry and in medical research in a university environment.

Klaus Kühn, former Chief Financial Officer of Bayer AG (2002 to 2010), has more than 30 years of experience in executive positions primarily in the chemical and pharmaceutical industry with a focus on finance and accounting.

The shareholders of 4SC AG also approved all of the resolutions proposed to the Annual General Meeting by the Management Board and the Supervisory Board with the required majority, including the following items:
• Resolution on the approval of the remuneration system for members of the Management Board;
• Approval of a control and profit transfer agreement between 4SC AG and 4SC Discovery GmbH;
• Resolution on the creation of new Authorized Capital, adjusted to the share capital that was raised following the capital increase in June 2012;
• Resolution on a new authorization of the Management Board to issue convertible bonds, bonds with warrants, profit participation rights and/or income debentures and create corresponding Conditional Capital.

A total of 78.3% of the voting capital was represented at the 2012 Annual General Meeting of 4SC AG.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
Friday, June 26, 2015
4SC Presents Final Results from Phase I AEGIS Trial at ASCO
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability.
Thursday, June 04, 2015
4SC Signs Licensing and Development Agreement with Menarini
Licensing partnership for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan.
Thursday, April 16, 2015
Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join 4SC AG
Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn.
Saturday, January 17, 2015
BEYOND RESEARCH Initiative of 4SC Discovery and CRELUX Reaches First Milestone
Compounds for inhibiting oxygen radicals and associated signalling pathways optimized for developing innovative therapies for degenerative diseases.
Tuesday, January 13, 2015
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucial role in cell division and tumour growth.
Friday, December 12, 2014
4SC Further Strengthens Patent Protection for its Lead Compound Resminostat
US Patent granted for the manufacturing process of resminostat.
Tuesday, October 21, 2014
4SC's Partner Yakult Honsha Completes Phase I Part of Clinical Study with Resminostat in NSCLC Patients
Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian NSCLC patients.
Saturday, October 11, 2014
CRELUX and 4SC Discovery Awarded Research Grant
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme.
Thursday, July 24, 2014
4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
Dr Erich Enghofer joins 4SC in the newly created position of Executive Vice President.
Friday, July 04, 2014
4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study
Company will present data from Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO.
Friday, May 30, 2014
4SC Discovery Receives EU Grant Worth EUR 450,000
Three-year research collaboration with the Medical Clinic of the University of Munich includes a project for identification and optimization of new compounds against a novel epigenetic target molecule.
Thursday, April 17, 2014
4SC Discovery Collaborates with Heidelberg University Hospital
The two-year R&D project is aimed at delivering a lead compound that can be brought to clinical development with the help of potential partners.
Friday, March 21, 2014
4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!